1-4 of 4
Emmanuel Bissé
Close
Sort by
Journal Articles

Fetal Hemoglobin (HbF) Induction during Initial Decitabine (DAC) Treatment of Elderly High-Risk MDS and AML Patients: A Potential Dynamic Biomarker for Outcome

Julia Stomper, Gabriele Ihorst, Stefan Suciu, Philipp Nikolaus Sander, Heiko Becker, P.W. Wijermans, Emmanuel Bissé, Rainer Claus, Michael Lübbert
Journal: Blood
Blood (2017) 130 (Supplement 1): 4261.
https://doi.org/10.1182/blood.V130.Suppl_1.4261.4261
Published: 2017
Journal Articles

Elevated Pre-Treatment Fetal Hemoglobin Predicts Better Outcome in MDS/AML Patients Receiving 5-Aza-2'-Deoxycytidine (DAC)

Rainer Claus, MD, Gabriele Ihorst, PhD, Philipp Sander, Ljudmila Bogatyreva, Heiko Becker, MD, Pierre W Wijermans, MD, Stefan Suciu, Emmanuel Bissé, MD PhD, Michael Lübbert, MD
Journal: Blood
Blood (2016) 128 (22): 3175.
https://doi.org/10.1182/blood.V128.22.3175.3175
Published: 2016
Journal Articles

Induction of an Erythroid but Not Megakaryocytic Expression Signature in Myeloid Cells By in Vitro 5-Aza-2'-Deoxycytidine Treatment

Rainer Claus, MD, Philipp Sander, Dietmar Pfeifer, PhD, Lioudmila Bogatyreva, Emmanuel Bissé, MDPhD, Michael Lübbert, MDPhD
Journal: Blood
Blood (2015) 126 (23): 4538.
https://doi.org/10.1182/blood.V126.23.4538.4538
Published: 2015
Journal Articles

Hemoglobin F Induction Is Frequent during Low-Dose 5-aza-2′-Deoxycytidine Treatment of Older AML/MDS Patients.

Rainer Claus, MD, Björn Hackanson, MD, Lena Kasten, Björn Rüter, MD, Emmanuel Bisse, MD PhD, Dieter Pfeifer, PhD, Michael Lübbert, MD PhD
Journal: Blood
Blood (2006) 108 (11): 4573.
https://doi.org/10.1182/blood.V108.11.4573.4573
Published: 2006